Overview

* Ensysce reports Q3 net loss of $3.7 mln, driven by increased R&D expenses

* Company initiates Phase 3 study of PF614, marking a major milestone

* Ensysce completes $4 mln preferred stock financing to support development

Result Drivers

* Cash and cash equivalents were $1.7 million as of September 30, 2025, compared to $3.5 million as of December 31, 2024

* R&D expenses were $3.0 million for the third quarter of 2025 compared to $1.7 million for the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$1.29

Q3 Net -$3.7

Income mln

Analyst Coverage

* Wall Street's median 12-month price target for Ensysce Biosciences Inc ( ENSC ) is $26.23, about 92.1% above its November 13 closing price of $2.07

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)